GlassScriptPhysician profile
Dena Barker
NPI 1124403977
$1,291.72
in general payments reported to CMS, 2019-2025
17 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $307 · 2023: $228 · 2024: $348 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $364.22 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $342.98 | 2023-2025 | |
| Dexcom, INC. | $100.06 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $99.35 | 2022-2025 | |
| Lilly USA, LLC | $55.33 | 2022-2025 | Mounjaro, Zepbound |
| Verona Pharma, INC. | $49.89 | 2025 | Ohtuvayre |
| Pfizer INC. | $44.25 | 2024-2025 | |
| Insulet Corporation | $38.66 | 2024-2025 | Omnipod |
| Averitas Pharma INC. | $33.59 | 2024 | Qutenza |
| Philips North America LLC | $31.08 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.74 | 2023 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $20.92 | 2024 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $20.09 | 2025 | |
| Amgen INC. | $18.77 | 2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $18.73 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.23 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dena Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.